A Study of Talquetamab and Teclistamab Each in Combination With a Programmed Cell Death Receptor-1 (PD-1) Inhibitor for the Treatment of Participants With Relapsed or Refractory Multiple Myeloma
The purpose of the study is to identify the safe dose(s) of a PD-1 inhibitor in
combination with talquetamab or teclistamab, and to characterize the safety and
tolerability of talquetamab or teclistamab when administered in combination with a PD-1
inhibitor.
Age: 18 years - 66+
Gender: All
Comparison of Anti-coagulation and Anti-Platelet Therapies for Intracranial Vascular Atherostenosis
The primary goal of the trial is to determine if the experimental arms (rivaroxaban or
ticagrelor or both) are superior to the clopidogrel arm for lowering the 1-year rate of
ischemic stroke, intracerebral hemorrhage, or vascular death.
Age: 30 years - 66+
Gender: All
Ultrasound-facilitated, Catheter-directed, Thrombolysis in Intermediate-high Risk Pulmonary Embolism
There are many available treatments for pulmonary embolism (PE), but the best treatment
for this condition is not known. The HI-PEITHO study will compare two treatment options
that are both available on the market for the treatment of PE.
Patients will be randomize...
Age: 18 - 80 years
Gender: All
Ultrasound-facilitated, Catheter-directed, Thrombolysis in Intermediate-high Risk Pulmonary Embolism
There are many available treatments for pulmonary embolism (PE), but the best treatment for
this condition is not known. The HI-PEITHO study will compare two treatment options that are
both available on the market for the treatment of PE.
Patients will be random...
Age: 18 - 80 years
Gender: All
Precision-Based Genomics in Prostate Cancer
Background:
Prostate cancer is the most common cancer and the second leading cause of death in males
in the United States. Researchers want to find additional gene mutations that may
increase a man s risk for prostate cancer and may affect how aggressive the diseas...
Age: 18 years - 66+
Gender: Male
Precision-Based Genomics in Prostate Cancer
Background: Prostate cancer is the most common cancer and the second leading cause of death in males in the United States. Researchers want to find additional gene mutations that may increase a man s risk for prostate cancer and may affect how aggressive the disease is....
Age: 18 years - 66+
Gender: Male
Precision-Based Genomics in Prostate Cancer
Background: Prostate cancer is the most common cancer and the second leading cause of death in males in the United States. Researchers want to find additional gene mutations that may increase a man s risk for prostate cancer and may affect how aggressive the disease is....
Age: 18 years - 66+
Gender: Male
LUMINOS-103: A Basket Trial Evaluating the Safety and Efficacy of PVSRIPO and PVSRIPO in Combination With Anti-PD-1/L1 Checkpoint Inhibitors in Patients With Advanced Solid Tumors
This is a Phase 1/2, open-label, multi-center, single arm basket study evaluating the
administration of PVSRIPO ± anti programmed cell death protein 1 (PD 1)/programmed
death-ligand 1 (PD L1) monoclonal antibody (mAb) (which will be referred to throughout this
pro...
Age: 18 years - 66+
Gender: All
Polatuzumab Vedotin in Combination With Chemotherapy in Subjects With Richter's Transformation
This study evaluates the effectiveness and safety of Polatuzumab vedotin plus infusional
chemoimmunotherapy containing rituximab, etoposide, prednisone, cyclophosphamide and
hydroxydaunorubicin. This is a single arm study. Enrolled patients will receive up to six
...
Age: 18 years - 66+
Gender: All
Correlation Vitamin D Level to Endocrine Autoimmune Toxicity Due to Immune Checkpoint Inhibitors
The purpose of this research study is to see if the amount of vitamin D in ones blood makes it more or less likely to develop thyroid gland toxicity when being treated with immunotherapy that blocks the activity of proteins called programed death-1(PD-1) or programmed d...
Age: 18 years - 66+
Gender: All
Correlation Vitamin D Level to Endocrine Autoimmune Toxicity Due to Immune Checkpoint Inhibitors
The purpose of this research study is to see if the amount of vitamin D in ones blood makes
it more or less likely to develop thyroid gland toxicity when being treated with
immunotherapy that blocks the activity of proteins called programed death-1(PD-1) or
progra...
Age: 18 years - 66+
Gender: All
Tumor-Agnostic Precision Immuno-Oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study
TAPISTRY is a Phase II, global, multicenter, open-label, multi-cohort study designed to
evaluate the safety and efficacy of targeted therapies or immunotherapy as single agents
or in rational, specified combinations in participants with unresectable, locally
advanced...
Age: Birth - 66+
Gender: All
A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Alone for Patients With a Form of Head and Neck Cancer Positive for Human Papilloma Virus 16 and Expressing the Protein PD-L1
An open-label, controlled, multi-site, interventional, 2-arm, Phase II trial of BNT113 in
combination with pembrolizumab vs pembrolizumab monotherapy as first line treatment in
patients with unresectable recurrent or metastatic HPV16+ HNSCC expressing programmed
cell...
Age: 18 years - 66+
Gender: All
Surveillance and Treatment to Prevent Fetal Atrioventricular Block Likely to Occur Quickly (STOP BLOQ)
Fetal complete (i.e., third degree, 3°) atrioventricular block (AVB), identified in the 2nd
trimester of pregnancy in an otherwise normally developing heart, is almost universally
associated with maternal anti-Ro autoantibodies and results in death in a fifth of cas...
Age: 18 years - 66+
Gender: Female
Antithrombotic Therapy to Ameliorate Complications of COVID-19 ( ATTACC )
Endothelial injury as a consequence of SARS-CoV-2 infection leads to a dysregulated host inflammatory response and activation of coagulation pathways. Macro- and micro-vascular thrombosis may contribute to morbidity, organ failure, and death. Therapeutic anticoagulation...
Age: 18 years - 66+
Gender: All
Antithrombotic Therapy to Ameliorate Complications of COVID-19 ( ATTACC )
Endothelial injury as a consequence of SARS-CoV-2 infection leads to a dysregulated host
inflammatory response and activation of coagulation pathways. Macro- and micro-vascular
thrombosis may contribute to morbidity, organ failure, and death. Therapeutic anticoagulati...
Age: 18 years - 66+
Gender: All
A Phase II Trial of Neoadjuvant Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) With Chemoradiation
Stomach cancer is the fifth most common digestive cancer and third main cause of death from
cancer in the world. Modern management of Gastric cancer involves a multi-disciplinary
approach involving surgical oncologists, medical oncologists, gastroenterologists and
...
Age: 18 years - 66+
Gender: All
Use of ReDS Technology in Patients With Acute Heart Failure
Background: Fluid overload, especially pulmonary congestion, is one of the main contributors into heart failure (HF) readmission risk and it is a clinical challenge for clinicians. The Remote dielectric sensing (ReDS) system is a novel electromagnetic energy-based techn...
Age: 18 years - 66+
Gender: All
Sickle Cell Disease and CardiovAscular Risk - Red Cell Exchange Trial (SCD-CARRE)
The SCD-CARRE trial is a Phase 3, prospective, randomized, multicenter, controlled, parallel
two-arm study aimed to determine if automated exchange blood transfusion and standard of care
administered to high mortality risk adult SCD patients reduces the total number...
Age: 18 years - 66+
Gender: All
Roflumilast or Azithromycin to Prevent COPD Exacerbations (RELIANCE)
A multi-center, randomized, 72-month, parallel- group, non-inferiority, phase III study to
compare the effectiveness of roflumilast (Daliresp, 500 mcg quaque die (QD) or alternate
regimen) therapy versus azithromycin (250 mg QD, 500 mg QD three times per week, or al...
Age: 40 years - 66+
Gender: All